Pharmaceutical start-up AcadeMab Biomedical Inc (研生生醫) said it has been developing a COVID-19 antibody drug, an endeavor not being undertaken by many other Taiwanese pharmaceutical firms.
The company was spun off from Academia Sinica’s Institute of Cellular and Organismic Biology in 2020 and has only 16 employees. It has set its sights on the innovative field of the monoclonal antibody treatment of tumors.
The start-up began developing antibody drugs in January, after seeing that COVID-19 vaccines could not effectively protect people from new variants of SARS-CoV-2, AcadeMab Biomedical chief strategy officer Pearl Fong (俸清珠) said in an interview with the Taipei Times on Thursday.
Photo courtesy of AcadeMab Biomedical Inc
The development of COVID-19 antibody drugs focuses on the sequences of the antibodies produced in the body following vaccination, Fong said.
The method does not require any information on the sequences of SARS-CoV-2, she said.
“Specifically, we need to know the DNA sequences of the Y-shaped antibodies carried by people’s memory B cells. Once we obtain the sequences, we can replicate the antibodies,” she added.
The start-up for at least four weeks collected blood samples from five people who had received three doses of COVID-19 vaccines. It then used a method called “cell shorting” to isolate memory B cells and used genetic engineering to decode the sequences of the antibody, AcadeMab Biomedical project manager Chiang Pao-yin (姜伯穎) said.
Getting the right sequences was not easy, Chiang said.
A 20 to 30 milliliter blood sample contains about 40 million cells, from which about 100,000 memory B cells can be isolated, Chiang said.
Using advanced technology, the company initially obtained about 2,000 sequences of antibodies and selected 163 that were expected to be the most effective in fighting against SARS-CoV-2 variants, he said.
“It is like making a key. It must not only have the right shape to fit in the hole, but it also has to be long enough to be used. The right antibodies must not only bind with the spike protein of the virus, but bind firmly,” Chiang said.
The start-up selected 10 sequences and tested them against the Omicron subvariants of SARS-CoV-2 and eventually chose four that showed the most potential, Chiang said, adding that its experimental drug is called SB-001.
Explaining how antibody drugs fight against new SARS-CoV-2 variants while vaccines cannot, Fong said that vaccines and antibody drugs use different mechanisms.
Vaccines prompt the immune system to produce antibodies, but after a given period, only a few antibodies that are most effective against a variant remain in the body, Fong said.
However, it is possible that these antibodies cannot attack new subvariants, she said.
Developers of COVID-19 antibody drugs have deep knowledge of antibody sequences, Fong said.
“It’s like we have a database. We can always research which sequence works best against the latest subvariant and change our formula accordingly,” Fong said.
An antibody that does not work well against an older subvariant could be effective against a new subvariant, she added.
“That has been the case with Eli Lilly and Co. Its first two antibody drugs were approved, but they did not work against later Omicron subvariants. However, the company found another sequence and used it to develop a new antibody drug,” Fong said.
AcadeMab Biomedical is one of only a few Taiwanese companies working on COVID-19 antibody drugs, she said.
Fong said there are two reasons that Taiwanese companies prefer to develop COVID-19 vaccines over antibody drugs, with about 10 firms working on vaccines.
“First, vaccines use fewer proteins than antibody drugs, so vaccine developers can conduct research more easily with limited manufacturing capacity. Second, the requirements for clinical trials involving antibody drugs are much stricter than those for vaccines,” she said.
Antibody drugs are mainly used for treatment instead of prevention, Fong said, adding that they can be used for prevention in some cases, she said.
People who are planning to travel to high-risk areas could take the drugs before embarking on their trip, she said.
As AcadeMab Biomedical focuses on research, it plans to find a manufacturing partner to codevelop SB-001, Fong said, adding that the company has been in talks with several firms and hopes to finalize a deal by the end of this year.
It plans to apply for emergency use authorization in the US and hopes to start phase 1 human trials by June next year, she said.
SHARES DOWN: The top 10 companies all decreased in market value last year, due to COVID-19, Russia’s invasion of Ukraine, rising interest rates and global inflation Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) retained the top spot among the largest companies in the Asian supply chain in terms of market capitalization, Digitimes Research said. Citing its Asia Supply Chain Market Cap 100 rankings for last year, the research firm last week said TSMC’s market cap was US$378.45 billion, the highest among Asian suppliers, although it dropped by nearly US$200 billion during the year. The 34.3 percent fall in TSMC’s market cap was the largest decline of any company in the survey last year, but was typical of how many top-ranking companies fared. The top 10 in Digitimes’ rankings all saw
Sex worker Nina relies on an apartment in the Turkish city of Istanbul as a relatively safe space to meet clients, but the 29-year-old is worried about making enough to cover the rent after the landlord doubled the price. As a surge in inflation fuels a housing crisis in Turkey, LGBTQ+ sex workers like Nina say landlords are forcing them to accept huge rent hikes for fear of being evicted. Nina, who uses the pronouns they and them, worries about how they will pay the increased monthly rent of 8,000 Turkish lira (US$425.11) on top of rising bills. “There are gas, electricity, water,
Hon Hai Technology Group (鴻海科技集團), also known as Foxconn Technology Group (富士康科技集團) internationally, yesterday said it was confident that its performance would improve in the second half of this year. Investment plans related to electric vehicles (EVs) in different parts of the world are expected to gradually start coming to fruition, Hon Hai chairman Young Liu (劉揚偉) told reporters after leading a new year’s prayer at the company’s headquarters in New Taipei City’s Tucheng District (土城). Major challenges stemming from the COVID-19 pandemic and the Russia-Ukraine war continue to affect the global economy. However, Liu said that he expects a turnaround in
Singapore is seeing an influx of ultra-wealthy families from China looking to protect their wealth from a government that increasingly views them with suspicion. The Chinese Communist Party’s recent crackdowns on tech billionaires and tax-shy celebrities, as well as three years of “zero COVID” policies, have led many rich Chinese to look for a safe haven. Nervous over the fate of their fortunes, some of the country’s mega-rich have since booked tickets to Singapore, insiders said. The key Asian financial hub ticks all the boxes for relocating tycoons. Singapore has been ruled by one party for the past six decades, and labor strikes and